CSF3 and acute myeloid leukemia: We conducted a single‐center, phase 1 prospective study (ChiCTR2200065634) to evaluate the efficacy and safety of chidamide, demethylating drugs (azacitidine), cytarabine, aclacinomycin, and G‐CSF plus venetoclax (CDCAG‐VEN) in patients with R/R AML.